

# ADVERSE EFFECTS OF SARS-COV VACCINES: GLOBAL INSIGHTS AND THROMBOTIC EVENTS

Editors:

**Ravikant Gupta**  
**Sudha Vengurlekar**  
**Sachin Kumar Jain**

**Bentham Books**

# **Adverse Effects of SARS-CoV Vaccines: Global Insights and Thrombotic Events**

Edited by

**Ravikant Gupta**

*School of Pharmaceutical Sciences  
Lovely Professional University  
Punjab, India*

**Sudha Vengurlekar**

*Department of Pharmacy  
University Institute of Pharmacy  
Oriental University, Indore  
Madhya Pradesh, India*

&

**Sachin Kumar Jain**

*Department of Pharmacy  
Oriental College of Pharmacy and Research  
Oriental University, Indore  
Madhya Pradesh, India*

**Adverse Effects of SARS-CoV Vaccines:  
Global Insights and Thrombotic Events**

Editors: Ravikant Gupta, Sudha Vengurlekar and Sachin Kumar Jain

ISBN (Online): 979-8-89881-252-2

ISBN (Print): 979-8-89881-253-9

ISBN (Paperback): 979-8-89881-254-6

© 2026, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore,  
in collaboration with Eureka Conferences, USA. All Rights Reserved.

First published in 2026.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.org](mailto:permission@benthamscience.org).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

**Bentham Science Publishers Pte. Ltd.**

No. 9 Raffles Place

Office No. 26-01

Singapore 048619

Singapore

Email: [subscriptions@benthamscience.net](mailto:subscriptions@benthamscience.net)



## CONTENTS

<b>FOREWORD</b> .....	i
<b>PREFACE</b> .....	ii
<b>LIST OF CONTRIBUTORS</b> .....	iv
<b>CHAPTER 1 INTRODUCTION TO SARS-COV</b> .....	1
<i>Manish Pathak, Rupesh Kumar Pandey, Lubhan Singh, Amit Kumar, Shiv Shankar Shukla, Ravindra Kumar Pandey, Satyaendra Kumar Shrivastava and Priyanka Pandey</i>	
<b>OVERVIEW OF SARS-COV</b> .....	2
<b>DISCOVERY AND ORIGIN OF SARS-COV</b> .....	3
<b>STRUCTURE AND GENOMIC CHARACTERISTICS OF SARS-COV</b> .....	3
Transmission and Pathogenesis .....	4
Clinical Features and Diagnosis of SARS-CoV .....	5
Epidemiology of the SARS-CoV Outbreak .....	5
Public Health Response to SARS-CoV .....	6
Lessons Learned from SARS-CoV .....	6
<b>THE IMPACT OF SARS-COV ON GLOBAL HEALTH</b> .....	6
Immediate Impact on Healthcare Systems .....	7
Economic Consequences of the SARS-CoV Outbreak .....	7
Impact on Public Health Policies and Practices .....	8
International Collaboration and Coordination .....	8
Public Awareness and Behavior Change .....	9
Scientific Advancements and Research Initiatives .....	9
Preparedness for Future Pandemics .....	10
<b>CONCLUSION</b> .....	11
<b>ACKNOWLEDGEMENT</b> .....	11
<b>REFERENCES</b> .....	11
<b>CHAPTER 2 GLOBAL STRATEGIES AND IMPLEMENTATION EFFORTS FOR SARS-COV</b> .....	14
<i>Vaibhav Rajoriya, Ravikant Gupta, Sudha Vengurlekar, Sachin Kumar Jain, Vibha Rajoriya, Surbhi Chourasiya and Kamlesh Patel</i>	
<b>INTRODUCTION</b> .....	15
Background on SARS-CoV .....	15
<i>Risk factors Associate with COVID-19</i> .....	16
Importance of Global Strategies and Implementation Efforts .....	17
<i>Variants of SARS-CoV-2</i> .....	17
<b>GLOBAL SURVEILLANCE AND MONITORING</b> .....	18
CoViNet and Its Impact .....	18
Role of TAG-VE .....	19
<i>Joint Research Projects Related to SARS-CoV-2</i> .....	19
<i>Brequinar: A Promising Experimental Drug</i> .....	20
GISAID in Genomic Surveillance .....	21
<b>COVID-19 VACCINES CURRENTLY USED GLOBALLY</b> .....	21
mRNA Vaccines .....	21
Viral Vector Vaccines .....	21
Protein Subunit Vaccines .....	21
Whole Virus Vaccines .....	21
<b>DEVELOPMENT OF COVID-19 VACCINES</b> .....	22

Accelerated Vaccine Development .....	22
Global Collaboration .....	22
<b>TYPES OF COVID-19 VACCINES</b> .....	22
<b>CHALLENGES AND SUCCESSES IN GLOBAL VACCINATION EFFORTS</b> .....	22
COVAX Challenges .....	22
Successes in Global Vaccination Efforts .....	23
<b>PUBLIC HEALTH MEASURES</b> .....	23
Challenges of Implementing PHSM During a Pandemic .....	23
Testing, Contact Tracing, and Quarantine Protocols .....	24
<i>Strengthening Healthcare Infrastructure</i> .....	24
<i>Collaboration in Vaccine Distribution</i> .....	25
<i>Policy Frameworks for Disease Response</i> .....	25
Research and Development .....	25
<i>Current Studies on Treatments and Vaccines</i> .....	26
Innovations in Diagnostic Tools and Technologies .....	26
<i>Moderna's Updated Vaccine</i> .....	26
<i>Pfizer-BioNTech's Omicron-Adapted Vaccine</i> .....	26
Case Studies .....	27
<i>Case-Control Study in Cali, Colombia</i> .....	27
<i>SARS-CoV-2 Immune Portraits in Young Adults</i> .....	27
<i>SARS-CoV-2 Rebound and Antiviral Treatment</i> .....	27
Successful Implementation in India .....	28
<i>Pandemic Resilience Framework</i> .....	28
<i>Antiviral Activity of Indian Medicinal Plants</i> .....	28
Community Health Care Services Implementation .....	29
<i>Special District Continuing Care Units (SDCUs) and COVID Hubs</i> .....	29
<i>ZyCoV-D DNA Vaccine Approval</i> .....	29
<b>RESEARCH AND COLLABORATION</b> .....	29
<b>CHALLENGES AND FUTURE DIRECTIONS</b> .....	29
Preparing for Future Pandemics .....	30
<b>CONCLUSION</b> .....	30
<b>CHALLENGES AND RECOMMENDATIONS</b> .....	31
<b>CONCLUDING REMARKS</b> .....	32
<b>REFERENCES</b> .....	32

<b>CHAPTER 3 THROMBOTIC EVENTS AND COMPREHENSIVE RISK OF SARS-COV-2:</b>	
<b>AN OVERVIEW</b> .....	37
<i>Nimita Manocha and Jeevandeep Mishra</i>	
<b>INTRODUCTION</b> .....	37
<b>CLINICAL INDICATIONS OF SARS-COV RELATED TO THROMBOSIS</b> .....	39
Arterial Thrombosis .....	40
Venous Thromboembolism .....	40
<b>THROMBOSIS EVENTS AND PATHOLOGICAL MECHANISM UNDERLYING</b>	
<b>HYPERCOAGULABILITY</b> .....	41
Mechanisms of Inflammation in COVID-19 .....	41
Pathophysiology of Thrombosis and Inflammation in COVID-19 .....	42
Observations .....	43
<i>Pulmonary Predilection</i> .....	43
<i>Microthrombosis in the Lungs</i> .....	43
<i>Complement Activation and Inflammation</i> .....	43
<i>Endothelial Dysfunction</i> .....	43

<i>Relatively Less Systemic Spread</i> .....	43
Clinical Relevance .....	43
<b>RISK OF SARS-COV INFECTION RELATED TO THROMBOSIS</b> .....	44
SARS-CoV Infection and Cellular Components Involved in Thrombosis .....	44
<b>DIAGNOSTIC MARKERS FOR EARLY DETECTION OF THROMBOSIS</b> .....	45
D-dimer: First-line Diagnostics .....	45
Prothrombin Fragment 1+2 (F1+2): A Marker of Coagulation Activation .....	45
Thrombin-Antithrombin Complex (TAT): Reflecting Thrombin Generation and Inhibition .....	46
Platelet Activation Markers: P-Selectin and Soluble CD40 Ligand .....	46
Microparticles: Novel Markers for Thrombosis .....	46
Tissue Factor and Tissue Factor Pathway Inhibitor (TFPI) .....	46
Inflammatory Markers: C-Reactive Protein (CRP) and Interleukins .....	47
Fibrin Monomers: Indicators of Ongoing Coagulation .....	47
Genetic Markers: Factor V Leiden and Prothrombin Gene Mutation .....	47
<b>PREVENTIVE MEASURES AND THERAPEUTIC MANAGEMENT FOR COVID-1-ASSOCIATED THROMBOSIS</b> .....	49
Preventive Measures .....	49
Therapeutic Management of COVID-19-Associated Thrombosis Anticoagulant Therapy ...	50
Adjunctive Therapies Targeting Inflammation .....	50
Immunomodulatory Therapies .....	51
Risk Stratification and Monitoring .....	51
Post-Discharge Thromboprophylaxis .....	51
<b>CONCLUSION</b> .....	52
<b>REFERENCES</b> .....	52
<b>CHAPTER 4 BIOLOGICAL MECHANISM AND EPIDEMIOLOGICAL DATA OF SARS-COV-INDUCED THROMBOSIS</b> .....	58
<i>Blessy Jacob and Arpna Indurakhya</i> .....	
<b>INTRODUCTION</b> .....	59
An Overview of Thrombosis and its Significance in COVID-19. ....	59
Causes of Thrombosis .....	59
Relevance of Thrombosis in COVID-19 .....	59
Clinical Manifestations of Thrombosis in COVID-19 .....	60
Management and Prevention of Thrombosis in COVID-19 .....	60
Importance of Studying the Biological Mechanism and Epidemiology of COVID-1-induced Thrombosis .....	60
<b>BIOLOGICAL MECHANISM OF THROMBOSIS IN COVID-19</b> .....	61
Mechanism of Thrombus Formation .....	61
<i>Endothelial Injury (Damage to Blood Vessel Walls)</i> .....	61
<i>Hypercoagulability (Increased Clotting Tendency)</i> .....	61
<i>Stasis of Blood Flow (Slowed Blood Flow)</i> .....	61
Role of Inflammation and Cytokine Storm .....	62
<i>Inflammation in Thrombus Formation</i> .....	62
<i>Cytokine Storm and Thrombosis</i> .....	62
<i>Clinical Implications</i> .....	63
Endothelial Dysfunction and Coagulation Cascade Dysregulation .....	63
<i>Endothelial Dysfunction</i> .....	63
<b>EPIDEMIOLOGICAL DATA ON THROMBOTIC EVENTS IN SARS-COV AND SARS-COV-2</b> .....	65
Comparative Statistics .....	65
Pathophysiological Mechanisms Underlying SARS-CoV-Induced Thrombosis .....	66

Statistical Correlation Between Inflammatory Markers and Thrombotic Risk .....	66
Incidence and Prevalence of Thrombotic Events .....	67
Risk Factors Involved with COVID-19-induced Thrombosis .....	67
Variability in Thrombotic Events Across Different Populations .....	68
<i>Ethnic and Racial Differences</i> .....	68
<i>Age-Related Differences</i> .....	69
<i>Gender Differences</i> .....	69
<i>Regional and Socioeconomic Differences</i> .....	69
Blood Clots in the Deep Veins (Deep Vein Thrombosis, DVT) and Blockages in the Lungs (Pulmonary Embolism, PE) .....	69
<i>Pathophysiology</i> .....	69
<i>Risk Factors</i> .....	69
<i>Symptoms</i> .....	70
<i>Complications</i> .....	70
Pulmonary Embolism (PE) .....	70
<i>Pathophysiology</i> .....	70
<i>Risk Factors</i> .....	70
<i>Symptoms</i> .....	70
Microvascular Thrombosis and its Implications .....	70
<i>Pathophysiology of Microvascular Thrombosis</i> .....	70
<i>Clinical Implications of Microvascular Thrombosis</i> .....	71
Stroke and other Cerebrovascular Complications .....	71
<i>Risk Factors</i> .....	71
<b>DIAGNOSTIC CHALLENGES AND STRATEGIES</b> .....	71
Laboratory biomarkers for assessing thrombotic risks .....	72
Challenges in Distinguishing COVID-19-induced Thrombosis from other Thrombotic Disorders .....	73
<b>MANAGEMENT AND TREATMENT APPROACHES</b> .....	73
Anticoagulation Therapy Protocols .....	73
Role of Thrombolytic Therapy in Severe Cases [22] .....	74
Long-term Management and Follow-up Consideration .....	75
<i>Anticoagulation Therapy</i> .....	75
<i>Risk Factor Management</i> .....	75
<i>Managing Complications</i> .....	76
<i>Special Considerations</i> .....	76
<i>Psychosocial Support</i> .....	76
<i>Transition of Care</i> .....	77
<b>PUBLIC HEALTH RESPONSES AND RECOMMENDATIONS</b> .....	77
Guidelines for Thrombosis Prevention in COVID-19 Patients .....	77
Impact of vaccination on thrombotic risk .....	77
<i>General Findings on Thrombosis and Vaccination</i> .....	77
<i>Mechanisms and Risk Factors</i> .....	78
<i>Comparative Risk</i> .....	78
<i>Guidance and Recommendations</i> .....	79
Healthcare System Preparedness and Resource Allocation .....	79
<b>FUTURE RESEARCH DIRECTIONS</b> .....	80
Area for Further Investigation into Understanding Thrombosis Pathophysiology .....	80
Development of Targeted Therapies and Prevention Strategies .....	80
<i>Targeted Therapies for Thrombosis</i> .....	81
<i>Personalized Medicine Approaches</i> .....	81
<i>Prevention Strategies</i> .....	81

<i>Innovative Research Areas</i> .....	82
Global Collaboration and Data Sharing Initiatives .....	82
<b>CONCLUSION</b> .....	83
<b>REFERENCES</b> .....	83
<b>CHAPTER 5 MANAGEMENT AND TREATMENT OF SARS-COV- INDUCED THROMBOTIC EVENTS</b> .....	87
Arpna Indurkhya, Blessy Jacob, Rashmi Arora, Sunayana Rathore, Shehnaz Shaikh and <i>Ashish K. Parashar</i> .....	
<b>INTRODUCTION</b> .....	88
Overview of Thrombotic Events Associated with SARS-CoV-2 Infection .....	88
Importance of Effective Management Strategies .....	88
<b>PATHOPHYSIOLOGY OF THROMBOTIC EVENTS IN SARS-COV-2</b> .....	89
<b>CLINICAL MANIFESTATIONS AND TYPES OF THROMBOTIC EVENTS</b> .....	93
Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT) .....	93
<i>Vascular Damage</i> .....	93
<i>Venous Stasis</i> .....	93
<i>Hypercoagulability and Venous Thromboembolism</i> .....	93
<i>Pulmonary Embolism</i> .....	94
<i>Risk Factors Associated with DVT and PE</i> .....	95
<i>Symptoms of PE and DVT (Fig. 3)</i> .....	96
Stroke and Arterial Thrombosis .....	97
<i>Ischaemic Stroke</i> .....	97
<i>Risk Factors of Stroke</i> .....	98
<i>Epidemiology of Stroke</i> .....	98
<i>Warning Signs of Stroke</i> .....	99
<i>Microvascular Thrombosis and Disseminated Intravascular Coagulation (DIC)</i> .....	99
<b>DIAGNOSTIC APPROACH</b> .....	100
Imaging Modalities for Detecting Thrombotic Events .....	100
<i>Compression Ultrasonography</i> .....	100
<i>Multidetector CT Angiography for Diagnosing Pulmonary Embolism</i> .....	101
<i>Additional Diagnostic Imaging Techniques for Pulmonary Embolism and Probable Deep Vein Thrombosis</i> .....	102
<i>Methods of Diagnosis for Possible PE</i> .....	104
<i>Suspected DVT Imaging</i> .....	104
<i>Blood Coagulation Assessments in SARS-COVID-19</i> .....	106
Challenges in Diagnosing Thrombotic Events in COVID-19 Patients .....	109
<b>MANAGEMENT STRATEGIES</b> .....	110
Anticoagulation Therapy Protocols (Prophylactic and Therapeutic) .....	110
<i>Anticoagulation Treatment Guidelines</i> .....	110
<i>Therapeutic Anticoagulation Therapy</i> .....	110
<i>Risk Associated with Anticoagulant Therapy</i> .....	110
Role of Direct Oral Anticoagulants (DOACs) vs. Traditional Anticoagulants .....	110
Considerations for Thrombolytic Therapy in Severe Cases .....	111
<i>The Pathophysiology of COVID-19-related Thrombosis [118]</i> .....	112
<i>Indications for Thrombolytic Therapy [119]</i> .....	113
<i>Contraindications [119]</i> .....	113
<i>Risk Factors for Thrombotic Events [120]</i> .....	113
<b>SPECIAL CONSIDERATION</b> .....	114
Management of Thrombotic Incidents Involving People in Critical Condition .....	114

Thromboprophylaxis strategies in hospitalized and non-hospitalized COVID-19 patients [128, 129] .....	114
<b>CLINICAL OUTCOMES AND LONG-TERM MANAGEMENT</b> .....	115
Prognosis of COVID-19 Associated Thrombotic Events .....	115
Long-Term Complications and Follow-Up Considerations for the Management of COVID- 19 [131, 132] .....	115
Rehabilitation and Secondary Prevention Strategies .....	117
<i>Rehabilitation Strategies</i> .....	117
<i>Secondary Prevention Strategies</i> .....	118
<b>CHALLENGES IN MANAGEMENT</b> .....	118
Risk Assessment .....	119
<i>Risk of Thrombosis</i> .....	119
<i>Pharmacological Management</i> .....	119
<i>Thromboprophylaxis</i> .....	119
<i>Monitoring and Follow-Up</i> .....	120
<i>Clinical Trials and Research</i> .....	120
Adverse Effects of Anticoagulation Therapy .....	120
<i>Anticoagulation Therapy in SARS-CoV-2 Management</i> .....	121
Integration of management strategies in the context of COVID-19 care protocols .....	124
<i>Role of WHO</i> .....	125
<i>Innovations in Healthcare Practices</i> .....	125
<i>Managing the Issue of Short Staffing</i> .....	125
<i>Community-Based Approach</i> .....	125
<i>Psychological Support</i> .....	125
<b>FUTURE DIRECTIONS AND RESEARCH NEEDS</b> .....	126
Treatment Strategies .....	126
Comprehending and handling long-term COVID .....	126
Implication on Public Health .....	127
Importance for Future Preparedness .....	127
Areas for Further Investigation in Thrombosis Pathophysiology .....	127
<i>Understanding Mechanisms of Venous thromboembolism</i> .....	127
<i>Investigating the Link Between Inflammation and Thrombosis</i> .....	127
<i>Novel Therapeutic Targets</i> .....	128
<i>Risk Assessment and Personalized Treatment</i> .....	128
<i>Advanced Diagnostic Methods</i> .....	128
<i>Long-Term Outcomes and Monitoring</i> .....	128
Development of Personalized Treatment Approaches .....	128
<i>A greater risk of thrombotic incidents</i> .....	129
<i>Anticoagulation Approaches</i> .....	129
<i>Personalized Treatment with Therapeutic Anticoagulation</i> .....	129
<i>Importance of treatment biomarkers</i> .....	129
<i>Integration of Nanomedicine</i> .....	129
<b>CONCLUSION</b> .....	130
<b>REFERENCES</b> .....	130
<b>CHAPTER 6 GLOBAL PROSPECTIVES: CASE STUDIES AND NATIONAL RESPONSES</b> .....	143
<i>Rajesh Hadia, Rahul Trivedi, Rajesh Maheshwari, Sunil Kardani, Sunil Baile,     Varun Singh Saggi, Kinjal Patel, Cyril Sajan and Hemraj Singh Rajput</i>	
<b>INTRODUCTION</b> .....	144
<b>SARS-COV-2 AND THROMBOTIC EVENTS</b> .....	145
<b>INCIDENCE AND CLINICAL IMPLICATIONS OF THROMBOTIC EVENTS</b> .....	147

<b>METHODOLOGY</b>	147
Global Case Studies of Thrombotic Events in SARS-CoV-2 Patients	148
<i>Case Study 1: North America</i>	148
<i>Case Study 2: Europe</i>	149
<i>Case Study 3: Asia</i>	150
<i>Case Study 4: Africa</i>	150
<b>COMPARATIVE ANALYSIS OF NATIONAL RESPONSES</b>	151
Challenges and Successes in Managing Thrombotic Events	152
Ethical and Equity Considerations	153
<b>CONCLUSION</b>	154
<b>ACKNOWLEDGMENTS</b>	154
<b>REFERENCES</b>	155
<b>CHAPTER 7 SARS-COV REGULATORY AND POLICY IMPLICATIONS</b>	157
<i>Bincy Pothen and Shiv Shankar Tiwari</i>	
<b>INTRODUCTION</b>	158
Importance of Regulatory and Policy Measures in Controlling Outbreaks	158
Scope and Structure of the Chapter	158
<b>HISTORICAL CONTEXT OF SARS-COV</b>	158
Emergence in China (2002)	158
Epidemiological Overview and Global Spread	159
<i>Identification of the Virus</i>	159
<i>Post-Outbreak Developments</i>	159
<b>REGULATORY FRAMEWORKS AND PUBLIC HEALTH POLICIES</b>	160
Initial Public Health Response	160
Role of the World Health Organization (WHO)	160
National Public Health Policies	160
Legal and Ethical Considerations	161
Development of International Health Regulations (IHR)	161
<b>SURVEILLANCE AND REPORTING SYSTEMS IN PUBLIC HEALTH</b>	162
Importance of Surveillance and Reporting Systems	162
Types of Surveillance Systems	162
Key Components of Effective Surveillance Systems	163
Global Surveillance Systems	163
Technological Advances in Surveillance	164
Challenges in Surveillance and Reporting	164
Role in Pandemic Preparedness and Response	165
<b>QUARANTINE AND ISOLATION POLICIES</b>	165
Definitions and Differences	165
Historical Context	165
Implementation of Quarantine and Isolation	166
Quarantine and Isolation in Recent Outbreaks	166
Challenges and Ethical Considerations	167
Best Practices for Quarantine and Isolation	167
<b>TRAVEL RESTRICTIONS AND BORDER CONTROL</b>	168
Types of Travel Restrictions and Border Control Measures	168
Historical Use of Travel Restrictions	169
Effectiveness of Travel Restrictions	169
Challenges and Limitations	169
Legal and Ethical Considerations	170

<b>VACCINE DEVELOPMENT AND DISTRIBUTION: A CRITICAL COMPONENT OF GLOBAL HEALTH SECURITY</b>	170
Introduction to Vaccine Development	170
Accelerated Vaccine Development	171
Global Vaccine Distribution	172
Vaccine Rollout and Implementation	172
Monitoring and Evaluation	173
Ethical Considerations in Vaccine Distribution	173
Future Directions in Vaccine Development and Distribution	174
<b>TREATMENT AND THERAPEUTIC REGULATIONS</b>	174
The Therapeutic Development Process	174
Accelerated Regulatory Pathways	175
Therapeutic Guidelines and Protocols	175
Regulatory Challenges in Public Health Crises	175
Case Studies in Therapeutic Regulation	176
Post-Market Surveillance and Safety Monitoring	176
Access and Equity in Therapeutic Distribution	177
<b>FUTURE DIRECTIONS IN THERAPEUTIC REGULATION</b>	177
<b>COMMUNICATION AND PUBLIC INFORMATION</b>	177
Importance of Communication in Public Health	177
Principles of Effective Public Health Communication	178
Communication Strategies in Public Health Crises	178
Digital Communication and Social Media	179
Challenges in Public Health Communication	179
Ethical Considerations in Public Health Communication	180
<b>ETHICAL AND HUMAN RIGHTS CONSIDERATIONS</b>	180
Ethical Principles in Public Health	180
Ethical Challenges in Public Health Interventions	181
<b>INTERNATIONAL COOPERATION AND POLICY HARMONIZATION</b>	181
Importance of International Cooperation	181
Global Health Organizations and Frameworks	181
<b>FUTURE DIRECTIONS AND PREPAREDNESS</b>	182
Strengthening Global and National Health Regulations	182
<b>IMPROVING SURVEILLANCE AND EARLY WARNING SYSTEMS</b>	182
<b>STRENGTHENING CRISIS COMMUNICATION AND PUBLIC TRUST</b>	183
<b>REGULATING PHARMACEUTICAL AND VACCINE DEVELOPMENT</b>	183
<b>STRENGTHENING HEALTHCARE INFRASTRUCTURE AND WORKFORCE CAPACITY</b>	184
<b>UNIVERSAL HEALTH COVERAGE (UHC) FOR PANDEMIC RESILIENCE</b>	184
<b>STRENGTHENING GLOBAL HEALTH GOVERNANCE AND COORDINATION</b>	185
<b>CONCLUSION</b>	185
Key Points	186
<b>REFERENCES</b>	186
<b>CHAPTER 8 CONCLUSION: BALANCING THERAPEUTIC BENEFIT AND RISK.</b>	192
<i>Sourabh D. Jain, Sampat Singh Tanwar, Seema Sharma and Kanhaiya Lal</i>	
<b>INTRODUCTION</b>	193
Development of Therapeutics	193
mRNA Vaccines: A Transformative Approach	194
Monoclonal Antibody Therapies	194
Global Vaccine Rollout and Public Health Strategies	195

Evolving Therapeutics: From Prevention to Post-Exposure Prophylaxis .....	195
Long-Term Perspectives and Impacts of Therapeutic Advances .....	195
Diverse Approaches to Vaccine Distribution and Public Health Guidelines .....	196
WHO's Role in Setting Standards and Addressing Vaccine Equity .....	196
<b>CHALLENGES OF EQUITABLE VACCINE DISTRIBUTION .....</b>	<b>197</b>
Public Health Strategies and Emergency Responses .....	197
Lessons Learned and Future Implications .....	198
Coagulopathy and COVID-19 .....	198
<b>MECHANISMS OF THROMBOTIC EVENTS IN COVID-19 .....</b>	<b>199</b>
Endothelial Cell Dysfunction .....	199
Immune and Inflammatory Responses .....	199
Platelet Activation and Aggregation .....	200
Complement Activation .....	200
Hypoxia and Hemostatic Dysregulation .....	201
Clinical Presentation and Diagnosis of COVID-19-Related Thrombotic Events .....	201
Management and Treatment Strategies .....	201
Future Directions in Research and Therapeutic Approaches .....	202
Clinical Presentation of COVID-19-Associated Thrombosis .....	202
Venous Thromboembolism (VTE) .....	203
Arterial Thrombosis .....	203
Microvascular Thrombosis .....	203
Disseminated Intravascular Coagulation (DIC) .....	203
Pathophysiology of COVID-19-Associated Coagulopathy .....	203
Treatment Strategies for COVID-19-Associated Thrombosis .....	204
Anticoagulation Therapy .....	204
Additional Antithrombotic Agents .....	204
Fibrinolytic Therapy .....	205
Immunomodulatory Therapy .....	205
Mechanical Interventions .....	205
<b>CLINICAL CONSIDERATIONS AND CHALLENGES .....</b>	<b>205</b>
Risk of Bleeding .....	205
Timing and Dosing of Anticoagulation .....	206
Role of Biomarkers in Management .....	206
Emerging and Investigational Therapies .....	206
Complement Inhibitors .....	206
NET (Neutrophil Extracellular Trap) Inhibitors .....	206
Janus Kinase (JAK) Inhibitors .....	207
Anti-Platelet Agents .....	207
Tissue Factor Pathway Inhibitors .....	207
Sphingosine-1-Phosphate (S1P) Receptor Modulators .....	207
Global responses .....	208
Early Lockdowns and Aggressive Measures: New Zealand and South Korea .....	208
Impact of Delayed Responses: The United States and Brazil .....	208
Balancing Economic and Public Health Goals: Sweden's Controversial Strategy .....	209
Comprehensive Public Health Strategies: Germany and Taiwan .....	209
Vaccine Distribution Challenges and Equitable Access: Global Disparities .....	210
<b>CASE STUDIES IN ADAPTATION AND RESILIENCE: AUSTRALIA AND THE</b>	
<b>UNITED ARAB EMIRATES .....</b>	<b>210</b>
Emergency Use Authorization (EUA) and Regulatory Flexibility .....	212
The Role of Real-World Evidence (RWE) and Adaptive Clinical Trials .....	212
Long-COVID and Post-acute Sequelae Research Prioritization .....	213

<b>ENHANCED VACCINE MONITORING AND SAFETY STANDARDS</b> .....	213
Post-Marketing Surveillance and Pharmacovigilance .....	214
Advanced Surveillance Technologies .....	214
Global Harmonization of Safety Standards .....	214
Risk-Benefit Communication and Public Trust .....	214
Adaptive Regulatory Frameworks .....	215
<b>PREPARING FOR FUTURE SARS-RELATED PATHOGENS AND PANDEMIC</b>	
<b>    READINESS</b> .....	215
Ethical and Transparency Considerations in Emergency Authorization .....	215
Anticipating Variants and Adaptation of Regulatory Processes .....	216
Expanding Regulatory Capacity for Diagnostics and Treatment Combinations .....	217
Therapeutic Developments and Innovations .....	218
Risk-Benefit Analysis and Regulatory Frameworks .....	220
Addressing Long-COVID and Persistent Health Effects .....	221
Global Health Equity and Vaccine Accessibility .....	221
Ethical Considerations in Treatment and Vaccine Rollout .....	222
Preparedness for Future Health Threats .....	222
Striking the Balance between Benefit and Risk in COVID-19 Management .....	222
<b>    GAPS IN SAFETY ASSESSMENT: LONG-TERM ADVERSE EFFECTS,</b>	
<b>    PHARMACOVIGILANCE, AND VARIANT IMPACT ON TREATMENT EFFICACY</b> ....	223
Long-Term Adverse Effects of COVID-19 Treatments .....	223
The Role of Pharmacovigilance Systems .....	223
Impact of Emerging Variants on Treatment Efficacy .....	224
<b>    SAFETY CONCERNS, REGULATORY CHALLENGES, AND COMPARATIVE</b>	
<b>    EFFECTIVENESS OF COVID-19 TREATMENTS</b> .....	224
Safety Concerns .....	224
Regulatory Challenges .....	225
Comparative Effectiveness of Treatments .....	225
<b>    UPCOMING ADVANCEMENTS IN SARS-COV-2 TREATMENT</b> .....	226
Antiviral Medications .....	226
Innovative Vaccine Delivery Systems .....	227
Domestic Vaccine Production .....	227
Broad-Spectrum Antiviral Agents .....	227
Monoclonal Antibody Therapies .....	227
Inhaled Therapies .....	228
<b>CONCLUSION</b> .....	228
<b>REFERENCES</b> .....	229
<b>SUBJECT INDEX</b> .....	457

## FOREWORD

The COVID-19 pandemic has underscored the importance of vaccines in safeguarding public health. The rapid development and deployment of COVID-19 vaccines have been a monumental achievement, saving countless lives and reducing the burden on healthcare systems worldwide. However, as with any medical intervention, it is essential to remain vigilant and responsive to potential adverse effects, such as the thrombotic events associated with certain COVID-19 vaccines.

'**Adverse Effects of SARS-CoV Vaccines: Global Insights and Thrombotic Events**' is a timely and essential book that addresses these concerns head-on. As a public health expert, I understand the critical role of transparent communication and evidence-based research in maintaining public trust in vaccination programs. This book exemplifies these principles by providing a detailed and nuanced exploration of vaccine-related thrombotic events.

The authors have meticulously compiled data from various studies, offering insights into the epidemiology, mechanisms, and clinical management of these rare but significant events. By doing so, they provide a balanced perspective that acknowledges the risks while also highlighting the overwhelming benefits of vaccination. This balanced approach is crucial for public health messaging, ensuring that individuals can make informed decisions about their health.

Moreover, this book serves as a guide for healthcare professionals, policymakers, and researchers, providing practical recommendations for monitoring and addressing thrombotic risks. It underscores the importance of ongoing research and surveillance in the dynamic landscape of vaccine safety.

I believe this book will be an invaluable resource in the continued efforts to promote vaccine safety and efficacy. It is a testament to the authors' dedication to public health and their commitment to advancing our understanding of this important issue. I highly recommend it to anyone seeking to understand the complexities of vaccine-induced thrombotic events and the broader implications for public health.

**Sheetu**  
COD (Pharmaceutics)  
School of Pharmaceutical Sciences  
Lovely Professional University  
Phagwara, Punjab, India

## PREFACE

In the wake of the global COVID-19 pandemic, the development and deployment of vaccines have been hailed as monumental achievements in medical science, saving millions of lives and enabling societies to regain a semblance of normalcy. However, with the rapid pace of vaccine development and distribution, certain side effects have emerged, prompting a need for in-depth analysis and understanding. One such concern is the occurrence of thrombotic events—blood clotting issues—associated with specific COVID-19 vaccines.

This book, "**Adverse Effects of SARS-CoV Vaccines: Global Insights and Thrombotic Events**," aims to provide a comprehensive examination of these phenomena. It is designed for a diverse audience, including healthcare professionals, researchers, policy-makers, and the general public. Our goal is to elucidate the mechanisms behind vaccine-induced thrombotic events, present current research findings, and offer practical guidance for managing and mitigating these risks.

The initial reports of thrombotic events in vaccinated individuals understandably caused alarm and raised questions about the safety of certain COVID-19 vaccines. In response, scientific communities and regulatory bodies worldwide have conducted extensive investigations to determine the prevalence, causality, and potential mechanisms of these events. Through these efforts, much has been learned, yet there remains a need for clear communication and continued research to fully understand and address these risks.

This book is structured to provide a logical progression from foundational concepts to specific case studies and recommendations. We begin with an overview of the blood clotting process, detailing the physiological mechanisms that maintain hemostasis and how these can be disrupted. We then delve into the specific thrombotic risks observed with some COVID-19 vaccines, exploring both the epidemiological data and the biological hypotheses that seek to explain these occurrences.

In subsequent chapters, we present detailed analyses of clinical case studies, regulatory responses, and the evolving guidelines for vaccination practices. Additionally, we include contributions from leading experts in hematology, immunology, and public health, offering a multifaceted perspective on the issue.

As we navigate the complexities of vaccine safety and public health, it is crucial to approach the topic with both scientific rigor and compassionate understanding. Vaccine-related thrombotic events, while rare, are a significant concern that must be addressed with evidence-based strategies to ensure the continued trust and confidence in vaccination programs.

We hope this book serves as a valuable resource, fostering a deeper understanding of thrombotic events related to COVID-19 vaccines and contributing to the ongoing discourse on vaccine safety. By shining a light on this critical issue, we aim to support informed decision-making and promote the health and well-being of individuals and communities worldwide.

This work would not have been possible without the contributions of many dedicated individuals. We extend our gratitude to the researchers, clinicians, and healthcare professionals who have tirelessly investigated and reported on vaccine safety. Special thanks are due to the patients and their families who have shared their experiences, contributing to the collective knowledge that underpins this book. We also appreciate the efforts of

regulatory bodies and public health organizations for their commitment to safeguarding public health. Finally, we are grateful to our readers for their interest and engagement with this important topic.

**Ravikant Gupta**

School of Pharmaceutical Sciences  
Lovely Professional University  
Punjab, India

**Sudha Vengurlekar**

Department of Pharmacy  
University Institute of Pharmacy  
Oriental University, Indore  
Madhya Pradesh, India

&

**Sachin Kumar Jain**

Department of Pharmacy  
Oriental College of Pharmacy and Research  
Oriental University, Indore  
Madhya Pradesh, India

## List of Contributors

- Amit Kumar** Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh-250005, India
- Arpna Indurkhya** Department of Pharmaceutics, Sri Aurobindo Institute of Pharmacy, Indore, Madhya Pradesh, India
- Blessy Jacob** Department of Pharmaceutical Chemistry, T. John College of Pharmacy, Bengaluru, Karnataka, India
- Bincy Pothen** Uttaranchal College of Health Sciences, Uttaranchal University, Dehradun, Uttarakhand, India
- Cyril Sajan** Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, 391760, Gujarat, India
- Hemraj Singh Rajput** Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, 391760, Gujarat, India
- Jeevandeep Mishra** Department of Pharmaceutical Chemistry, Indore Institute of Pharmacy, Indore, 453331, India  
Department of Pharmaceutics, Indore Institute of Pharmacy, Indore, 453331, India
- Kamlesh Patel** Vedic Institute of Pharmaceutical Education and Research, Sagar, Madhya Pradesh, India
- Kinjal Patel** Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, 391760, Gujarat, India
- Kanhaiya Lal** Department of Research and Development, Patanjali Laboratories, Haridwar, Uttarakhand, India
- Lubhan Singh** Department of Pharmacology, Faculty of Pharmacy, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh-250005, India
- Manish Pathak** Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh-250005, India
- Nimita Manocha** Department of Pharmaceutical Chemistry, Indore Institute of Pharmacy, Indore, 453331, India
- Priyanka Pandey** Department of Pharmaceutics, NKBR College of Pharmacy, Meerut, Uttar Pradesh-250005, India
- Rupesh Kumar Pandey** Department of Pharmacology, Faculty of Pharmacy, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh-250005, India
- Ravindra Kumar Pandey** Department of Pharmacognosy, Columbia Institute of Pharmacy, Raipur, Chhattisgarh-492001, India
- Ravikant Gupta** School of Pharmaceutical Sciences, Lovely Professional University, Punjab, India
- Rashmi Arora** Department of Pharmacology, College of Dental Science and Hospital, Indore, Madhya Pradesh, India
- Rajesh Hadia** Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, 391760, Gujarat, India

<b>Rahul Trivedi</b>	Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, 391760, Gujarat, India
<b>Rajesh Maheshwari</b>	Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, 391760, Gujarat, India
<b>Shiv Shankar Shukla</b>	Department of Pharmacognosy, Columbia Institute of Pharmacy, Raipur, Chhattisgarh-492001, India
<b>Satyaendra Kumar Shrivastava</b>	Department of Pharmacognosy, Parijat College of Pharmacy, Indore, Madhya Pradesh-452001, India
<b>Sudha Vengurlekar</b>	University Institute of Pharmacy, Oriental College of Pharmacy and Research, Oriental University, Indore, Madhya Pradesh, India
<b>Sachin Kumar Jain</b>	University Institute of Pharmacy, Oriental College of Pharmacy and Research, Oriental University, Indore, Madhya Pradesh, India
<b>Surbhi Chourasiya</b>	Vedic Institute of Pharmaceutical Education and Research, Sagar, Madhya Pradesh, India
<b>Sunayana Rathore</b>	Department of Pharmaceutics, Sri Aurobindo Institute of Pharmacy, Indore, Madhya Pradesh, India
<b>Shehnaz Shaikh</b>	Department of Pharmaceutics, Sri Aurobindo Institute of Pharmacy, Indore, Madhya Pradesh, India
<b>Sunil Kardani</b>	Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, 391760, Gujarat, India
<b>Shiv Shankar Tiwari</b>	Uttaranchal College of Health Sciences, Uttaranchal University, Dehradun, Uttarakhand, India
<b>Sourabh D. Jain</b>	Department of Pharmaceutical Chemistry, Chameli Devi institute of Pharmacy, Indore, Madhya Pradesh, India
<b>Sampat Singh Tanwar</b>	Department of Pharmacy, Vaishnav Vidyapeeth Vishwavidyalaya, Indore, Madhya Pradesh, India
<b>Seema Sharma</b>	Department of Pharmacy, Vaishnav Vidyapeeth Vishwavidyalaya, Indore, Madhya Pradesh, India
<b>Vaibhav Rajoriya</b>	Vedic Institute of Pharmaceutical Education and Research, Sagar, Madhya Pradesh, India University Institute of Pharmacy, Oriental College of Pharmacy and Research, Oriental University, Indore, Madhya Pradesh, India
<b>Vibha Rajoriya</b>	Vedic Institute of Pharmaceutical Education and Research, Sagar, Madhya Pradesh, India
<b>Varun Singh Saggi</b>	Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, 391760, Gujarat, India

## CHAPTER 1

### Introduction to SARS-CoV

**Manish Pathak<sup>1</sup>, Rupesh Kumar Pandey<sup>2,\*</sup>, Lubhan Singh<sup>2</sup>, Amit Kumar<sup>1</sup>, Shiv Shankar Shukla<sup>3</sup>, Ravindra Kumar Pandey<sup>3</sup>, Satyaendra Kumar Shrivastava<sup>4</sup> and Priyanka Pandey<sup>5</sup>**

<sup>1</sup> *Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh-250005, India*

<sup>2</sup> *Department of Pharmacology, Faculty of Pharmacy, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh-250005, India*

<sup>3</sup> *Department of Pharmacognosy, Columbia Institute of Pharmacy, Raipur, Chhattisgarh-492001, India*

<sup>4</sup> *Department of Pharmacognosy, Parijat College of Pharmacy, Indore, Madhya Pradesh-452001, India*

<sup>5</sup> *Department of Pharmaceutics, NKBR College of Pharmacy, Meerut, Uttar Pradesh-250005, India*

**Abstract:** This chapter provides a comprehensive introduction to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), the virus responsible for the SARS outbreak in 2002-2003. It begins by detailing the discovery of the virus, highlighting its classification within the Coronaviridae family and its zoonotic origins. The chapter then explores the molecular biology of SARS-CoV, including its genomic structure, replication cycle, and the mechanisms it employs to infect host cells. Key clinical features of SARS-CoV infection are discussed, along with the epidemiology and transmission dynamics that facilitated its rapid spread across continents. Furthermore, the chapter addresses diagnostic methods, therapeutic approaches, and preventive measures that were developed in response to the outbreak. By contextualizing SARS-CoV within the broader framework of coronavirus research, this chapter lays the foundation for understanding the emergence and impact of related viruses, including SARS-CoV-2, the causative agent of the COVID-19 pandemic.

**Keywords:** COVID-19, Clinical features, Pandemic, SARS-CoV, Zoonotic origins.


---

\* **Corresponding author Rupesh Kumar Pandey:** Department of Pharmacology, Faculty of Pharmacy, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh-250005, India; Tel: +91-9826678198; E-mail: ranu.rupeshpandey@gmail.com

## OVERVIEW OF SARS-COV

Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) emerged as a novel and highly infectious pathogen in the early 21<sup>st</sup> century, causing a global outbreak that began in 2002. This virus belongs to the Coronaviridae family, which consists of large, enveloped, single-stranded RNA viruses that primarily infect the respiratory tract of humans and other animals [1]. SARS-CoV was the first of two highly pathogenic coronaviruses to emerge in recent decades, the second being the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in 2012.

SARS-CoV was responsible for the 2002-2003 SARS epidemic, which affected over 8,098 people (WHO, 2004) and resulted in 774 deaths (CDC, 2004) across 26 countries. The rapid spread of the virus, coupled with its ability to cause severe respiratory illness, raised major concerns among public health officials and led to widespread efforts to contain the outbreak [2]. Although the epidemic was successfully controlled by mid-2003, the emergence of SARS-CoV demonstrated the potential for coronaviruses to cause pandemics [3], emphasizing the necessity for ongoing surveillance and research (Fig. 1).



**Fig. (1).** Simplified diagram of SARS-CoV, illustrating its structure and key proteins.

## DISCOVERY AND ORIGIN OF SARS-COV

SARS-CoV was first identified in February 2003 after reports of atypical pneumonia cases in Guangdong province, China [4]. The initial outbreak quickly spread to Hong Kong and other parts of the world, triggering an urgent response from global health authorities, including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC).

Early investigations revealed that SARS-CoV likely originated in bats, serving as a natural reservoir for many coronaviruses. The virus is believed to have jumped from bats to civet cats, a species sold in live animal markets in China, before finally crossing over to humans [5]. This zoonotic transmission pathway, where an infectious disease is transmitted from animals to humans, was a significant factor in the rapid spread of SARS-CoV.

## STRUCTURE AND GENOMIC CHARACTERISTICS OF SARS-COV

SARS-CoV is an enveloped virus with a positive-sense, single-stranded RNA genome that is approximately 29.7 kilobases long, making it one of the largest RNA genomes among known viruses [6]. The viral genome encodes several structural and non-structural proteins critical for its replication and ability to infect host cells [7].

The structure of SARS-CoV includes four major structural proteins:

- **Spike (S) Protein:** Facilitates viral entry into host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor on human cells. The S protein is the primary target for neutralizing antibodies and is a key focus for vaccine development.
- **Membrane (M) Protein:** Involved in viral assembly and plays a crucial role in maintaining the shape of the virus.
- **Envelope (E) Protein:** A small structural protein that participates in the assembly and release of the virus from host cells.
- **Nucleocapsid (N) Protein:** Encapsulates the viral RNA genome, protecting it from degradation and aiding in its replication.

The genomic organization of SARS-CoV is typical of coronaviruses, with two large open reading frames (ORF1a and ORF1b) encoding non-structural proteins that form the viral replicase complex [8]. Downstream of these ORFs are genes encoding the structural proteins S, E, M, and N, as well as several accessory proteins that contribute to the virus's ability to evade the host immune response (Fig. 2).

## Global Strategies and Implementation Efforts For SARS-CoV

Vaibhav Rajoriya<sup>1,2,\*</sup>, Ravikant Gupta<sup>3</sup>, Sudha Vengurlekar<sup>2</sup>, Sachin Kumar Jain<sup>2</sup>, Vibha Rajoriya<sup>1</sup>, Surbhi Chourasiya<sup>1</sup> and Kamlesh Patel<sup>1</sup>

<sup>1</sup> Vedic Institute of Pharmaceutical Education and Research, Sagar, Madhya Pradesh, India

<sup>2</sup> University Institute of Pharmacy, Oriental College of Pharmacy and Research, Oriental University, Indore, Madhya Pradesh, India

<sup>3</sup> School of Pharmaceutical Sciences, Lovely Professional University, Punjab, India

**Abstract:** The global response to SARS-CoV has necessitated a multifaceted approach, incorporating surveillance, vaccination, public health measures, healthcare preparedness, and international collaboration. This chapter examines the comprehensive strategies and implementation efforts undertaken worldwide to combat the virus. It begins with an overview of SARS-CoV and the critical need for coordinated global strategies. The role of genomic surveillance and international data sharing is emphasized, highlighting the importance of real-time monitoring. Vaccination strategies are explored, detailing the development, distribution, and challenges in achieving widespread immunization. The effectiveness of public health measures, such as universal face mask usage, social distancing, and extensive testing and contact tracing, is underscored as crucial in controlling viral outbreaks. The discussion also addresses the critical need for healthcare system preparedness, including fortifying infrastructure and prioritizing the safety and protection of healthcare workers. By addressing these components, we can enhance our collective ability to manage health crises effectively. The chapter further explores the significant contributions of international organizations, such as the WHO, to policy-making and fostering global cooperation. Ongoing research and development efforts are reviewed, showcasing innovations in treatments, vaccines, and diagnostic tools. Through case studies, the paper presents successful implementation examples from various countries, offering valuable lessons and best practices. Finally, the challenges faced—including vaccine hesitancy and misinformation—are discussed, along with recommendations for future pandemic preparedness. This comprehensive analysis underscores the importance of unified global efforts in managing and mitigating the impact of SARS-CoV.

---

\* Corresponding author Vaibhav Rajoriya: Vedic Institute of Pharmaceutical Education and Research, Sagar, Madhya Pradesh, India; & University Institute of Pharmacy, Oriental University, Indore, Madhya Pradesh, India; E-mail: rajoriyavaibhav@gmail.com

**Keywords:** International collaboration, Immunization, Vaccination, Public health, Policy making, SARS-CoV, WHO.

## **INTRODUCTION**

### **Background on SARS-CoV**

The COVID-19 pandemic was caused by SARS-CoV-2, which first emerged in Wuhan, China, in December 2019. This single-stranded, positive-sense RNA virus shares genetic similarities with SARS-CoV-1, the agent behind the SARS outbreak of 2002–2004. Although its zoonotic origins and transmission methods remain subjects of study, research suggests that SARS-CoV-2 most likely originated from bats. The virus primarily spreads through aerosols, respiratory droplets, and close contact. Public health measures, such as physical distancing and mask usage, have proven essential in mitigating the transmission of the disease. Even in cases of breakthrough infections, vaccination has demonstrated its effectiveness as a barrier against severe disease and death. Ongoing research seeks to enhance our understanding of the virus's behavior and evolution. Coronaviruses (CoVs), a broad family of viruses, are responsible for human respiratory diseases such as SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome). MERS, discovered in 2012, and SARS, identified in 2003, have both shown significant fatality rates. When SARS-CoV-2 initially infected humans, it was a zoonotic virus, most likely transmitted from animals to humans. Identifying its source is critical for controlling outbreaks and informing public health interventions. SARS-CoV-2 belongs to a genetically related group that includes SARS-CoV, the virus responsible for the 2003 SARS outbreak, as well as other coronaviruses found in bat populations. These bats, primarily of the *Rhinolophus* genus, are distributed across Asia, Africa, the Middle East, and Europe [1].

SARS-CoV-1, the virus responsible for the 2002–2004 SARS outbreak, had a significant international impact. The outbreak began in Foshan, Guangdong, China, in November 2002. By February 2003, the World Health Organization (WHO) was alerted, and a global alert followed in March 2003. Initially, the cause was uncertain, and some media outlets speculated that it might have been an influenza virus. The outbreak's primary phase lasted approximately eight months. Although sporadic cases were reported until May 2004, the WHO declared SARS controlled on July 5, 2003. The response involved multidisciplinary, multinational, and highly complex efforts. The emergence of SARS-CoV-2, a similar coronavirus, in Wuhan, China, in late 2019 led to the ongoing COVID-19 pandemic [2]. By binding to the Angiotensin-converting Enzyme 2 (ACE2) receptor, SARS-CoV-1, an enveloped, positive-sense, single-stranded RNA virus,

primarily targets the epithelial cells of the lungs. It causes severe respiratory illnesses in humans, bats, and palm civets. Initial symptoms include muscle pain, headache, and fever, which progress to respiratory issues such as coughing, dyspnea, and pneumonia within 2-14 days. A decrease in lymphocyte count is often observed in patients with SARS. The virus had a mortality rate of around 9%, with older individuals—particularly those over 60—being more at risk. Effective public health measures, such as testing, isolation, quarantine, and travel restrictions, were instrumental in controlling the outbreak. Isolating symptomatic patients proved especially critical in limiting the virus's spread. SARS-CoV-2, the virus responsible for COVID-19, is closely related to SARS-CoV-1. Although both viruses cause severe respiratory illnesses, COVID-19 has had a far-reaching global impact [3].

Common symptoms of SARS-CoV-2 infection include fever or chills, a persistent cough, difficulty breathing, sore throat, nasal congestion, runny nose, and a sudden loss of taste or smell. Fatigue, muscle or body aches, headaches, nausea, vomiting, and diarrhea are common symptoms of SARS-CoV-2 infection [4]. These symptoms typically manifest between 2 to 14 days after exposure and can range from mild to severe. SARS-CoV-2 has a strong affinity for human cell receptors, allowing it to invade human cells efficiently. Unlike any known coronaviruses found in domestic or agricultural animals, SARS-CoV-2 has no genetic connection to them. The first cases of COVID-19 were reported in Wuhan City, China, in December 2019, with numerous early cases linked to the Huanan Wholesale Seafood Market. This market functioned as a trading hub for various animal species. SARS-CoV-2 shares genetic similarities with the virus responsible for the 2003 SARS outbreak and is believed to have zoonotic origins, likely involving bats. Investigating these origins is vital for shaping effective responses to COVID-19 and advancing therapies [5].

### ***Risk factors Associate with COVID-19***

Chronic fatigue, characterized by persistent and debilitating exhaustion, significantly impacts daily activities and quality of life. Cognitive impairment, often referred to as brain fog, presents challenges with concentration, memory, and clear thinking. Autonomic dysfunction, which affects the autonomic nervous system, can disrupt the regulation of heart rate, blood pressure, and breathing. Post-exertional malaise further complicates recovery, as symptoms tend to worsen after physical or mental exertion. Additionally, prolonged effects of SARS-CoV infection may increase the risk of developing other health conditions, including diabetes, cardiovascular diseases, blood clots, and neurological disorders.

## CHAPTER 3

# Thrombotic Events and Comprehensive Risk of SARS-CoV-2: An Overview

Nimita Manocha<sup>1,\*</sup> and Jeevandeep Mishra<sup>1,2</sup>

<sup>1</sup> Department of Pharmaceutical Chemistry, Indore Institute of Pharmacy, Indore- 453331, India

<sup>2</sup> Department of Pharmaceutics, Indore Institute of Pharmacy, Indore- 453331, India

**Abstract:** The global impact of Coronavirus disease 2019 (COVID-19) and its devastating clinical effects, resulting in several million infections and close to five million deaths, has created alarm worldwide. In-depth studies and ongoing research are being continuously conducted on the clinical manifestations caused by the SARS virus.

Studies, supported with clinical data, have suggested that there is an increased incidence rate of thrombotic events associated with SARS-CoV-2. The COVID-19 infection is a thrombo-inflammatory disorder, implicating a hyperinflammatory response, platelet activation, and triggering of the coagulation cascade. COVID-19 has been associated with increased rates of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), and arterial thromboses, including acute ischemic stroke and peripheral arterial thrombosis.

This chapter describes the thrombotic events caused by SARS-CoV-19 and the comprehensive risks related to it. It is important to understand the pathophysiological mechanisms, at both the molecular and cellular levels, that may underlie thrombotic complications in SARS-CoV-2 infection. Most of the clinical manifestations are interrelated, leading to drastic clinical effects that may be reported later and found to be linked to COVID-19. Ongoing research is the need of the hour to effectively manage, by prevention and therapeutic treatment, COVID-19-associated thromboembolism to reduce concomitant morbidity and mortality.

**Keywords:** Arterial thromboses, Platelet activation, SARS-CoV-2, Thromboembolism, Venous thromboses.

## INTRODUCTION

The current global scenario of the effects of the COVID-19 pandemic is devastating, with millions of people reported dead and many having long-term

---

\* Corresponding author Nimita Manocha: Department of Pharmaceutical Chemistry, Indore Institute of Pharmacy, Indore-453331, India; E-mail: Nimita.manocha@indoreinstitute.com

health effects; this range of long-term health effects is referred to as “long COVID”.

The outbreak of SARS-CoV-2, the virus responsible for COVID-19, has had far-reaching and transformative effects on global health, economies, societies, and geopolitics. Emerging in late 2019, this novel coronavirus rapidly escalated into a pandemic, affecting public health and reshaping daily life around the world.

Severe Acute Respiratory Syndrome (SARS) has been identified as the cause of various significant health issues affecting patients worldwide. One reason for its severity is its ability to rapidly spread, which has led to widespread health concerns since its emergence. SARS not only poses a direct threat to respiratory function but also triggers a range of systemic complications, including inflammatory responses, organ damage, and even multi-organ failure. The global impact of SARS extends beyond health implications, also affecting healthcare systems, economies, and societal structures, which is owed to its rapid transmission and, further to it, the challenges associated with containment and treatment. Understanding the diverse medical issues associated with SARS remains crucial for effective public health responses, treatment strategies, and ongoing research efforts aimed at mitigating its impact on global health. The long-term consequences will continue to unfold as pharmacovigilance accumulates data for clinical research assessment [1].

Thrombotic events are a serious complication of Severe Acute Respiratory Syndrome (SARS), including infections caused by coronaviruses such as SARS-CoV and its successor, SARS-CoV-2. These events, majorly characterized by the formation of blood clots within the vasculature, have been identified as complications associated with viral respiratory infections. COVID-19, caused by SARS-CoV-2, has particularly highlighted the intricate interplay between viral infection and thrombosis.

It is significant to understand the mechanisms underlying this phenomenon, which include endothelial dysfunction, cytokine storm-induced inflammation, and a hypercoagulable state. The severe effects are the diverse thrombotic manifestations, ranging from deep vein thrombosis and pulmonary embolism to arterial thrombosis, leading to strokes and myocardial infarctions.

Ongoing research continues to unravel the pathophysiological links between SARS-CoV-2 infection and thrombosis, aiming to refine preventive strategies and therapeutic interventions.

Advanced age, obesity, and pre-existing cardiovascular diseases exacerbate these risks. Prophylactic anticoagulation has become standard practice in hospitalized COVID-19 patients to mitigate thrombotic complications.

The coagulation cascade, platelet activation, and a hyperinflammatory response are three distinct but related pathophysiological pathways that may be involved in infection-induced thrombosis [2, 3].

### CLINICAL INDICATIONS OF SARS-COV RELATED TO THROMBOSIS

SARS-CoV-2, the virus responsible for COVID-19, has been associated with various thrombotic complications. The clinical indications related to thrombosis in COVID-19 are:

- **Venous Thromboembolism (VTE):** Patients with COVID-19 have shown an increased risk of developing Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), mainly observed in severe cases and among those with pre-existing risk factors.
- **Hypercoagulability:** COVID-19 can induce a hypercoagulable state, characterized by elevated levels of D-dimer, fibrinogen, and other coagulation markers. This condition increases the risk of clot formation.
- **Microvascular Thrombosis:** Some patients experience microvascular thrombosis, which can contribute to organ dysfunction, particularly in the lungs (resulting in acute respiratory distress syndrome) and kidneys.
- **Stroke:** There have been reports of increased incidence of ischemic strokes in COVID-19 patients, likely related to both thromboembolic events and underlying inflammation.
- **Increased Platelet Activation:** Studies have shown that SARS-CoV-2 can lead to platelet activation, contributing to thrombosis.
- **Acute Coronary Syndrome:** There is also evidence that COVID-19 may precipitate acute coronary syndrome due to thrombosis in the coronary arteries.
- **Prolonged Immobility:** Hospitalization and prolonged immobility during severe illness can further increase the risk of thrombotic events [4].

Management often involves anticoagulation, particularly in hospitalized patients, to mitigate these risks. Early identification and monitoring are crucial for preventing serious complications related to thrombosis.

Approximately one-third of hospitalized severe COVID-19 patients experience macrovascular thrombotic complications, which are linked to an elevated risk of hospital mortality. Microvascular thrombosis, a pathological occlusion of arterioles, capillaries, and venules (microvessels) by platelet-and/or fibrin-rich thrombi, is a significant aspect of the course of COVID-19 [5]. Coagulation

## Biological Mechanism and Epidemiological Data of SARS-CoV-Induced Thrombosis

Blessy Jacob<sup>1\*</sup> and Arpna Indurakhya<sup>2</sup>

<sup>1</sup> Department of Pharmaceutical Chemistry, T. John College of Pharmacy, Bengaluru, Karnataka, India

<sup>2</sup> Department of Pharmaceutics, Sri Aurobindo Institute of Pharmacy, Indore, Madhya Pradesh, India

**Abstract:** Serious respiratory conditions, such as COVID-19, have been linked to thrombotic complications, where the virus triggers a cascade of biological events leading to thrombosis. This peculiarity is essentially determined by the infection's cooperation with host cells through its spike protein, which binds to angiotensin-converting enzyme II (ACE-II) receptors, primarily situated on respiratory epithelial cells and endothelial cells. Upon entry, SARS-CoV infects not only respiratory cells but also endothelial cells that line the blood vessels. Various diseases can lead to endothelial dysfunction, characterized by an increased presence of pro-inflammatory cytokines like interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and others. These cytokines foster a favorable thrombotic environment by activating endothelial cells and triggering the release of tissue factor (TF), a vital initiator of the coagulation cascade. Additionally, SARS-CoV can directly activate platelets and leukocytes through various mechanisms, further contributing to thrombus formation. Viral proteins and inflammatory mediators released during infection can induce platelet aggregation and adhesion to endothelial cells, promoting thrombus formation in blood vessels.

Furthermore, the virus-induced inflammatory response can disrupt the delicate balance between pro-coagulant and anticoagulant factors in the bloodstream, tilting it towards a hypercoagulable state. Epidemiological data underscore the significant burden of thrombotic complications in severe COVID-19 cases. Understanding these patterns informs clinical management strategies aimed at reducing morbidity and mortality associated with SARS-CoV-induced thrombosis.

**Keywords:** Inflammatory response, Platelets, SARS-CoV, Thrombosis.

---

\* Corresponding author Blessy Jacob: Department of Pharmaceutical Chemistry, T. John College of Pharmacy, Bengaluru, Karnataka, India;  
E-mail: blessyjacob14@gmail.com

## INTRODUCTION

### An Overview of Thrombosis and its Significance in COVID-19.

Thrombosis occurs when a blood clot (thrombus) forms inside a blood vessel, obstructing blood flow. There are two main types [1]:

- **Venous Thrombosis:** This occurs when blood clots form in the veins, often in the legs (deep vein thrombosis, DVT). If the clot breaks off and travels to the lungs, it can cause a pulmonary embolism (PE), which is a life-threatening condition.
- **Arterial Thrombosis:** This occurs when blood clots form in the arteries and can lead to severe conditions such as a heart attack, stroke, or peripheral arterial disease.

### Causes of Thrombosis

- **Hypercoagulability:** An increased tendency of blood to clot.
- **Endothelial Injury:** Damage to the inner lining of the blood vessel.
- **Stasis of Blood Flow:** Sluggish or slow blood flow that promotes clotting.

### Relevance of Thrombosis in COVID-19

COVID-19, caused by the SARS-CoV-2 virus, has been closely associated with an increased risk of thrombosis, leading to serious complications in affected patients. The link between COVID-19 and thrombosis is multifaceted [2]:

- **Hypercoagulable State:** COVID-19 can induce a hypercoagulable state, where there is an increase in clotting factors such as D-dimer (fibrin degradation products), fibrinogen, and other substances that promote clotting. This increases the risk of both venous and arterial thrombosis.
- **Endothelial Dysfunction:** The SARS-CoV-2 virus can infect the endothelial cells that line blood vessels, causing inflammation (endotheliitis) and damage to the blood vessel walls. This exposes underlying tissue and activates the coagulation cascade, promoting blood clot formation.
- **Inflammatory Response (Cytokine Storm):** The body's acute inflammatory response to COVID-19, commonly referred to as the "cytokine storm", can disrupt normal coagulation pathways. In severe cases, this can lead to disseminated intravascular coagulation (DIC), a condition in which widespread clotting occurs throughout the body, consuming clotting factors and leading to both thrombosis and bleeding.
- **Immobilization and Hospitalization:** Hospitalized COVID-19 patients, especially those who are critically ill and immobilized for prolonged periods, are

at higher risk for venous thromboembolism (VTE). This includes conditions like deep vein thrombosis (DVT) and pulmonary embolism (PE).

### **Clinical Manifestations of Thrombosis in COVID-19**

COVID-19-related thrombosis can manifest in various ways, including:

- **Venous Thromboembolism (VTE):** Clots that form in the veins, potentially leading to DVT or PE.
- **Pulmonary Embolism (PE):** When a clot travels to the lungs, it can block blood flow and cause respiratory failure.
- **Microthrombosis:** Small blood clots that can form in the microvasculature, leading to complications such as acute respiratory distress syndrome (ARDS), acute kidney injury, and organ damage.
- **Arterial Thrombosis:** Clots that form in the arteries, potentially leading to heart attacks, strokes, or peripheral arterial disease.

### **Management and Prevention of Thrombosis in COVID-19**

- **Anticoagulation Therapy:** Given the heightened risk of thrombosis in COVID-19 patients, anticoagulation therapy is often recommended. This therapy helps prevent the formation of clots and reduces the likelihood of thrombotic complications, especially in hospitalized patients [3].
- **Prophylactic Anticoagulation:** Even non-critical COVID-19 patients may be recommended for prophylactic anticoagulation due to the increased risk of clotting. This is particularly important for patients who are immobilized, as well as those with other underlying risk factors for thrombosis.

### **Importance of Studying the Biological Mechanism and Epidemiology of COVID-19-induced Thrombosis**

Studying the biological mode of action and epidemiology of COVID-19-induced thrombosis is crucial for several reasons [4]:

- Improved Understanding of Disease Pathophysiology
- Optimizing Clinical Management
- Epidemiological Insights.
- Impact on Public Health
- Guiding Future Research
- Global Health Implications

**CHAPTER 5****Management and Treatment of SARS-CoV-Induced Thrombotic Events****Arpna Indurkhya<sup>1,\*</sup>, Blessy Jacob<sup>2</sup>, Rashmi Arora<sup>3</sup>, Sunayana Rathore<sup>1</sup>, Shehnaz Shaikh<sup>1</sup> and Ashish K. Parashar<sup>4</sup>**<sup>1</sup> Department of Pharmaceutics, Sri Aurobindo Institute of Pharmacy, Indore, Madhya Pradesh, India<sup>2</sup> Department of Pharmaceutical Chemistry, T. John College of Pharmacy, Bengaluru, Karnataka, India<sup>3</sup> Department of Pharmacology, College of Dental Science and Hospital, Indore, Madhya Pradesh, India<sup>4</sup> Lloyd Institute of Management and Technology, Greater Noida, Uttar Pradesh, India

**Abstract:** Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), a novel condition induced by viral infections, presents a significant challenge owing to its propensity to trigger thrombotic events. The current strategies for managing and treating SARS-CoV-induced thrombotic conditions primarily focus on early recognition and risk assessment based on age, comorbidities, D-dimer levels, severity of illness, and early detection through comprehensive diagnostic protocols such as imaging techniques and laboratory biomarkers. Treatment modalities that encompass anticoagulation therapy tailored to individual risk profiles and emerging therapies targeting specific pathophysiological mechanisms are also included. Anticoagulation therapy plays a central role, and tailored regimens based on thrombotic severity and patient-specific factors are recommended to prevent the progression and recurrence of thrombosis. Supportive care measures such as respiratory support and fluid management are essential for managing severe cases. Furthermore, the role of supportive care and preventive measures in mitigating complications associated with thrombosis has been emphasized. Finally, ongoing research initiatives and future directions aim to refine therapeutic approaches and improve outcomes for patients affected by SARS-CoV-induced thrombotic conditions. Thus, by implementing various strategies, healthcare providers can effectively manage thrombosis induced by SARS-CoV. Collaborative efforts among infectious disease specialists, hematologists, and intensivists are vital for optimizing outcomes in patients affected by SARS-CoV-induced thrombotic events.

**Keywords:** Early detection, Management, Strategies, SARS-CoV, Thrombotic.

\* **Corresponding author Arpna Indurkhya:** Department of Pharmaceutics, Sri Aurobindo Institute of Pharmacy, Indore, Madhya Pradesh, India; E-mail: indurkhyarpana@gmail.com

## INTRODUCTION

### Overview of Thrombotic Events Associated with SARS-CoV-2 Infection

Thrombotic events, particularly thrombosis in veins and arteries, are a prominent consequence of SARS-CoV-2 (COVID-19). These occurrences have been recorded in individuals with various disease severity levels and may contribute to COVID-19's high morbidity and fatality rates. There are greater thrombotic problems in severe cases, especially in ICU settings, around 29.4%, whereas in non-ICU settings, it is 11.5% [1]. Venous Thromboembolism (VTE), which includes Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT), has been observed in as many as 20–30% of COVID-19 patients who are very ill, especially those sent to intensive care units. Furthermore, peripheral arterial thrombosis, ischemic stroke, and arterial thrombosis (myocardial infarction or heart attack) have all been linked to COVID-19 in young individuals lacking typical risk factors [2]. Autopsy investigations on COVID-19 patients have revealed extensive microthrombosis in the pulmonary vasculature, which contributes to the severe Acute Respiratory Syndrome (ARDS) found in COVID-19 [3].


Individuals with pre-existing illnesses like cardiovascular disease, diabetes, obesity, and cancer face a higher risk, and prolonged immobility from serious illnesses can increase venous thrombosis risk. In COVID-19, older age and male sex are linked to a higher risk of thrombotic incidents [4].

A complex interplay of pro- and anti-thrombotic factors causes thrombosis in COVID-19 patients, increasing the risk of clinical thrombosis. Thrombosis is caused by elevated cytokines and chemokines that damage endothelial cells, stimulate platelet contact, and boost eicosanoid synthesis. Downregulation of anti-thrombotic mechanisms, leading to decreased fibrinolytic pathways and anti-thrombin III, exacerbates this pro-thrombotic state (Fig. 1). Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) is a rare syndrome affecting a few individuals who received adenoviral vector-based COVID-19 vaccines, including ChAdOx1 CoV-19 (AstraZeneca, University of Oxford, and Serum Institute of India) and Ad26. COV2. (Janssen, Johnson, and Johnson). VITT often occurs 5-10 days after inoculation and manifests as cerebral venous thrombosis [5].

### Importance of Effective Management Strategies

Thrombotic episodes can lead to long-term COVID symptoms, including exhaustion, breathing difficulties, and neurological disorders. Managing thrombosis efficiently can reduce the risk of long-term health concerns. SARS-

CoV-2 infection may cause microvascular thrombosis, leading to organ failure, such as Acute Respiratory Distress Syndrome (ARDS), kidney damage, and liver dysfunction. Effective therapeutic interventions are necessary due to the morbidity and mortality from thrombotic events caused by SARS-CoV-2. Myocardial Infarction (MI), ischemic stroke, and Pulmonary Embolism (PE) are life-threatening thrombotic events that increase mortality among COVID-19 patients, especially those severely ill. Effective management, including prophylactic and therapeutic anticoagulation, can reduce fatal events and help preserve organ function. Comprehensive strategies, including prophylaxis, early detection, and personalized treatment, can improve COVID-19 patient outcomes, ensuring better recovery and long-term health. These strategies are crucial as the pandemic evolves, with new variants and changing disease severity patterns [5, 6].



**Fig. (1).** Thrombosis caused by COVID-19 is caused by dysregulation of factors that promote and inhibit thrombosis [5].

## **PATHOPHYSIOLOGY OF THROMBOTIC EVENTS IN SARS-COV-2**

The pathophysiological mechanisms of thrombosis in COVID-19 are complex and multifactorial, involving direct viral effects, inflammatory responses, endothelial dysfunction, and coagulation pathway abnormalities. SARS-CoV-2, which causes COVID-19, not only causes respiratory illness but also generates hypercoagulability, increasing thrombotic event risk. These mechanisms are crucial for developing targeted therapies for prevention and management. Various mechanisms of COVID-19 thrombosis and their implications are mentioned in Table 1.

**CHAPTER 6****Global Prospectives: Case Studies and National Responses****Rajesh Hadia<sup>1\*</sup>, Rahul Trivedi<sup>1</sup>, Rajesh Maheshwari<sup>1</sup>, Sunil Kardani<sup>1</sup>, Sunil Baile<sup>1</sup>, Varun Singh Saggi<sup>1</sup>, Kinjal Patel<sup>1</sup>, Cyril Sajan<sup>1</sup> and Hemraj Singh Rajput<sup>1</sup>**<sup>1</sup> *Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara-391760, Gujarat, India*

**Abstract:** The novel COVID-19, provoked by SARS-CoV-2 infection, shed light on drastic worldwide health issues such as thrombotic events, including Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and arterial thrombosis. These conditions are the result of the ability of the virus to induce a predominance in thrombotic tendency or retention and loss of a balance from mechanisms related to endothelial dysfunction, systemic inflammation, and immune responses. It is critical to note that these thrombotic events are an important cause of morbidity and mortality in patients with COVID-19, especially those who are critically ill. Resource-rich nations across the world responded quite differently, generally preventing thrombotic complications *via* early intervention of known risks, sensitive diagnostics, and routine prophylactic anticoagulation. On the other hand, resource-limited nations were significantly disadvantaged, burdened with untreated thrombotic complications and inferior results. In addition, the identification of Vaccine-Induced Thrombotic and Thrombocytopenic syndrome (VITT) related to certain vaccines like AstraZeneca and Johnson & Johnson posed new challenges in striking a balance between the protective effects of vaccination with thrombotic risks. Resource-limited nations still have to stick with adenovirus-based vaccines, while mRNA vaccines were snatched quickly in the developed world to avoid these risks. Asymmetries in healthcare infrastructure, access to anticoagulants, ICU beds, and diagnostic testing capacity among different nations underline the importance of global cooperation and equal distribution of resources. This chapter will review the global approach to thrombotic management during the pandemic by detailing case studies from across nations and deducing common themes. It underlines the imperative to develop global healthcare infrastructure, diagnostic capacity, and international cooperation in good time to be ready for future pandemics which have a similar potential of coagulation disorders. To address thrombotic complications in under-resourced regions and to foster global health equity, it is critical to have sustainable strategies, as advocated by the World Health Organisation (WHO).

\* **Corresponding author Rajesh Hadia** Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara-31760, Gujarat, India; Tel: +91 9590677280; E-mail: docrajesh.hadia@gmail.com

**Keywords:** Anticoagulation therapy, COVID-19, Deep vein thrombosis, Global health disparities, Healthcare infrastructure, International collaboration, Pulmonary embolism, SARS-CoV-2, Thrombotic events, Vaccine-induced thrombotic thrombocytopenia.

## INTRODUCTION

The Novel Coronavirus Disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory Syndrome Virus 2 (SARS-CoV-2) has been a concern that resulted in increased thrombotic events, including Deep Venous Thrombosis (DVT), Pulmonary Embolism (PE), and arterial thromboses. The latter is a huge concern as well for carriers, even if they are vaccinated. These mechanisms seem to be driven, at least in part, by the induction of a hypercoagulable state consequent to SARS-CoV-2 infection, leading to clot production under both arterial and venous contexts through laydown of fibrin, suggesting angiopathy as well as a pro-inflammatory response mounted against endothelial injury. Thrombotic complications appear to occur with an alarmingly high frequency in some severely ill patients; up to 45% of hospitalized COVID-19 patients may experience VTE, and arterial thrombosis is associated with higher mortality. As a global health community, different strategies used in the management of these thrombotic risks depend on available healthcare infrastructure and resources worldwide to respond, irrespective of public health strategies. Proactive measures like these have enabled developed nations with technologically advanced medical infrastructure to largely mitigate this risk of thrombosis, resulting in significantly lower mortality rates. On the other hand, countries with poor resources, predominantly in Africa and South Asia regions, have encountered severe healthcare limitations that caused insufficient access to anticoagulation therapies, ICU beds, as well as diagnostic facilities, resulting in high incidences of untreated thrombotic complications and inferior patient outcomes. The discovery of Vaccine-Induced Thrombotic Thrombocytopenia (VITT) has resulted in prescription adjustments, affecting the young more than ever since it is even more frequent with adenovirus-based remedies such as AstraZeneca. Meds from the EU have a growing preference for mRNA vaccines instead. Prompt action is required to address these healthcare disparities and create sustainable strategies to manage thrombotic risks among the less-privileged nations of the world. International collaboration and initiatives—including WHO guidance for treatment approaches, as well as coordinating resource distribution of countries with limited capacities—are crucial efforts to support COVID-19-related thrombosis responses. The lessons from this pandemic would highlight the importance of developing global healthcare infrastructures, improving diagnostic capabilities, overseeing the fair distribution of medical resources, and international collaboration to be ready for future pandemics that impose a similar risk of

coagulation disorders.

## **SARS-COV-2 AND THROMBOTIC EVENTS**

The development of COVID-19 caused by SARS-CoV-2 has spawned a health emergency worldwide, not only for the severe respiratory illness that it provokes but also for secondary systemic conditions. Of these, thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE], and arterial thromboses) have garnered significant attention owing to their high morbidity and mortality rates, especially in hospitalized and critically ill patients. This has been particularly evident in COVID-19 patients, where the virus contributes to a thrombosis-prone nature. The SARS-CoV-2 virus modulates the body's hemostatic balance, generating a hypercoagulable state that promotes the development of blood clots in various parts of the body. This hypercoagulability is in large part a consequence of the virus binding to and infecting cells found within the vascular endothelium, which are crucial for blood flow regulation and prevention of heart-attack-like conditions. The virus infects cells through an Angiotensin-Converting Enzyme 2 (ACE2) receptor that is not only present in lung tissues but also located within the endothelium of blood vessels. SARS-CoV-2 binds these receptors, and the ensuing endothelial dysfunction makes the endothelium lose its protection. This inflammatory response leads to endothelial injury, which is an essential step in the process of thrombosis. The endothelial insult leads to the release of pro-thrombotic factors such as von Willebrand factor and tissue factor, which greatly increase in amounts, boosting the formation of clots. Also, this injury to the vasculature takes away the homeostasis and disturbs either the procoagulant or anticoagulant pathway due to others giving way, leading to thrombosis [1]. This interaction of the ACE2 receptor also causes vasculitis, inflammation of blood vessels, resulting in more clot formation, together with collateral ischemia. COVID-19 is further accompanied by an intense inflammatory response or “cytokine storm,” beyond the direct actions on the endothelium. Patterns of immune response and cytokine storm display excessive pro-inflammatory cytokine generation, including high levels of interleukin-6 (IL-6) and TNF- $\alpha$ ; these phenomena exacerbate the characteristics of systemic inflammation, which tends to trigger coagulation cascades. IL-6 in particular induces the synthesis of fibrinogen (a protein critical for blood clot formation), and TNF- $\alpha$  is known to exacerbate endothelial damage. These cytokines act synergistically on local and systemic levels to increase the risk of both microvascular and macrovascular thrombosis [2, 3]. Additionally, the higher concentration of these inflammatory mediators promotes thrombosis at a systemic level, resulting in microclots being formed within small vessels throughout the lungs, kidneys, liver, and even the brain itself, and consequentially unpredictably leading to multi-organ dysfunction. NETosis NETs are a specific mode of cell

## CHAPTER 7

# SARS-CoV Regulatory and Policy Implications

**Bincy Pothen<sup>1,\*</sup> and Shiv Shankar Tiwari<sup>2</sup>**

<sup>1</sup> *School of Management & Commerce Studies, Shri Guru Ram Rai University, Dehradun, Uttarakhand, India*

<sup>2</sup> *Uttaranchal College of Health Sciences, Uttarakhand University, Dehradun, Uttarakhand, India*

**Abstract:** The outbreak of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) underscored significant vulnerabilities in global public health systems, necessitating a reevaluation of regulatory frameworks and policy responses. This chapter explores the regulatory and policy implications arising from the SARS-CoV epidemic, highlighting the lessons learned and their relevance to contemporary pandemic preparedness. Key areas of focus include the role of international health regulations, the impact of national health policies, and the importance of coordinated global health governance. The SARS-CoV crisis revealed critical gaps in disease surveillance, reporting, and response coordination, prompting the World Health Organization (WHO) to strengthen the International Health Regulations (IHR). These regulations mandated member states to enhance their public health infrastructure, improve disease surveillance, and ensure timely reporting of health emergencies. Additionally, national governments implemented policies aimed at early detection, rapid response, and effective containment of infectious diseases. The chapter emphasizes the importance of transparent communication, robust public health systems, and continuous investment in healthcare infrastructure. It also discusses the role of scientific research in informing policy decisions and the need for adaptive regulatory frameworks to address emerging health threats. By examining the SARS-CoV outbreak, this chapter provides valuable insights into the essential components of effective pandemic preparedness and response strategies, underscoring the critical need for a cohesive and multi-faceted approach to global health security.

**Keywords:** Disease surveillance, Global health governance, Health crisis management, Infectious diseases, International Health Regulations, Pandemic preparedness, Policy implications, Public health infrastructure, Regulatory frameworks, SARS-CoV.

---

\* **Corresponding author Bincy Pothen:** School of Management & Commerce Studies, Shri Guru Ram Rai University, Dehradun, Uttarakhand, India; E-mail: pothen\_bincy@yahoo.co.in

## **INTRODUCTION**

Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) emerged in 2002–2003 as a novel and highly contagious virus, originating in Guangdong, China. The virus quickly spread to multiple countries, leading to over 8,000 cases and nearly 800 deaths. The global nature of the outbreak revealed weaknesses in public health systems and showcased the need for coordinated international responses. SARS-CoV significantly impacted global health, disrupting economies, healthcare infrastructure, and travel systems. It also served as a precursor to future pandemics, most notably COVID-19, highlighting the ongoing threat of zoonotic diseases and global viral outbreaks.

### **Importance of Regulatory and Policy Measures in Controlling Outbreaks**

Regulatory and policy measures are crucial in controlling the spread of infectious diseases like SARS-CoV. These measures include quarantine protocols, international travel restrictions, timely public health communication, and effective surveillance systems. The World Health Organization (WHO) and national bodies such as the Centers for Disease Control and Prevention (CDC) play a pivotal role in coordinating responses, enforcing legal frameworks, and ensuring the distribution of medical resources. These interventions help to contain the spread of the virus, reduce mortality, and ensure that healthcare systems remain functional during outbreaks.

### **Scope and Structure of the Chapter**

This chapter will examine the emergence of SARS-CoV, its impact on global health, and the role of regulatory and policy measures in outbreak control. Key sections will focus on the historical context of the virus, the epidemiology of its spread, and the effectiveness of international coordination in managing the outbreak. Additionally, the chapter will discuss the lessons learned from the SARS-CoV outbreak that have influenced global health responses to future epidemics. The role of healthcare systems, policy frameworks, and global health organizations will be highlighted throughout the discussion.

## **HISTORICAL CONTEXT OF SARS-COV**

### **Emergence in China (2002)**

SARS-CoV was first identified in November 2002 in Guangdong Province, southern China. The earliest cases involved individuals who had close contact with animals, particularly in markets where live wild animals were sold. It is believed that SARS-CoV originated from bats and was transmitted to humans

through an intermediate host, likely civet cats, which were commonly sold in these markets [1].

### **Epidemiological Overview and Global Spread**

The virus spread rapidly in the densely populated urban areas of Guangdong and neighboring regions. The initial outbreak was marked by a cluster of cases in healthcare workers, which highlighted the virus's ability to spread in healthcare settings. Despite efforts to contain the outbreak, the virus spread to Hong Kong, a major international travel hub, in early 2003. From Hong Kong, the virus quickly spread to other countries, including Vietnam, Singapore, Canada, and beyond [2].

As SARS-CoV spread to other countries, the severity of the illness and the speed of transmission caused widespread panic. The World Health Organization (WHO) issued global alerts, and many countries implemented strict travel restrictions and quarantine measures to prevent the spread of the virus. The outbreak led to significant social and economic disruptions, particularly in Asia, where tourism and trade were heavily affected [3].

### ***Identification of the Virus***

In March 2003, scientists identified the causative agent of SARS as a novel coronavirus, later named SARS-CoV. This marked the first time a coronavirus was linked to a severe respiratory illness in humans. The discovery of SARS-CoV prompted a global effort to understand the virus's origins, transmission, and potential for causing future outbreaks [4].

The global response to SARS was swift and coordinated. Governments, health agencies, and researchers worked together to implement strict public health measures, including isolation of infected individuals, contact tracing, and travel restrictions. These efforts, along with the natural course of the virus, led to the containment of the outbreak by mid-2003. The last known case of SARS occurred in July 2003, and the outbreak was officially declared over by the WHO in 2004 [5].

### ***Post-Outbreak Developments***

After the outbreak, research into coronaviruses intensified, leading to the identification of several related viruses in animals, particularly bats. This research highlighted the potential for future zoonotic transmission of coronaviruses to humans, which became a reality with the emergence of Middle East Respiratory Syndrome (MERS) in 2012 and COVID-19 (caused by SARS-CoV-2) in 2019 [6].

## Conclusion: Balancing Therapeutic Benefit and Risk

**Sourabh D. Jain<sup>1,\*</sup>, Sampat Singh Tanwar<sup>2</sup>, Seema Sharma<sup>2</sup> and Kanhaiya Lal<sup>3</sup>**

<sup>1</sup> Department of Pharmaceutical Chemistry, Chameli Devi institute of Pharmacy, Indore, Madhya Pradesh, India

<sup>2</sup> Department of Pharmacy, Vaishnav Vidyapeeth Vishwavidyalaya, Indore, Madhya Pradesh, India

<sup>3</sup> Department of Research and Development, Patanjali Laboratories, Haridwar, Uttarakhand, India

**Abstract:** The global response to the COVID-19 pandemic has necessitated a fine balance between therapeutic efficacy and minimizing adverse effects, including thrombotic events and systemic complications associated with SARS-CoV-2. This chapter explores the multifaceted nature of COVID-19 pathophysiology, highlighting key mechanisms such as hypercoagulability, cytokine storm syndromes, and endothelial dysfunction that contribute to disease severity. Global insights have informed risk stratification and mitigation strategies, integrating anticoagulation therapies, immunomodulatory approaches, and precision medicine. By emphasizing a comprehensive framework for risk-benefit analysis, this work underscores the critical importance of individualized treatment protocols and adaptive clinical guidelines to ensure patient safety and optimize therapeutic outcomes in the ongoing fight against SARS-CoV-2.

The emergence of SARS-CoV-2, the virus responsible for COVID-19, brought an unprecedented response from the scientific community. Unlike past outbreaks, SARS-CoV-2 had a rapid global spread, leading to wide-reaching consequences on health, economies, and societies. As a result, the pace of research and therapeutic development was significantly accelerated, with scientists worldwide collaborating to understand the virus's biology, transmission patterns, and potential treatment methods. The key areas of focus included antivirals, vaccines, monoclonal antibodies, and supportive therapies to address COVID-19's various symptoms and complications.

This chapter provides a comprehensive examination of the dual challenges of maximizing therapeutic benefit while minimizing harm in COVID-19 treatment. Drawing on global insights and evidence from clinical trials, it highlights the importance of precision medicine approaches, individualized risk stratification, and

---

\* Corresponding author **Sourabh D. Jain:** Department of Pharmaceutical Chemistry, Chameli Devi institute of Pharmacy, Indore, Madhya Pradesh, India; E-mail: sourabhjain072@gmail.com

adaptive clinical frameworks. As the world transitions from pandemic response to long-term management of SARS-CoV-2 and its complications, the lessons learned from balancing efficacy and safety will be essential for addressing not only COVID-19 but also future global health crises.

**Keywords:** COVID-19, mRNA technology, Public health, SARS-CoV-2, WHO guidelines.

## **INTRODUCTION**

The COVID-19 pandemic has reshaped global healthcare landscapes, exposing the challenges of managing a novel pathogen with widespread and unpredictable impacts. SARS-CoV-2, the causative agent of COVID-19, is associated with a broad spectrum of clinical manifestations, ranging from asymptomatic infection to severe disease characterized by Acute Respiratory Distress Syndrome (ARDS), thrombotic events, and multi-organ failure. These complications have prompted an urgent need to understand the virus's pathophysiology and develop therapies that effectively balance therapeutic benefit and associated risks.

One of the most significant challenges in COVID-19 management is the hypercoagulable state frequently observed in patients. Manifesting as venous thromboembolism, arterial thrombosis, or microvascular clot formation, these events are driven by a complex interplay of immune dysregulation, endothelial injury, and aberrant inflammatory responses, such as the cytokine storm. Despite advancements in therapeutic strategies, including anticoagulation protocols and immunomodulatory treatments, concerns regarding adverse effects, such as bleeding risks, remain a critical consideration.

### **Development of Therapeutics**

In the early stages of the pandemic, researchers rapidly evaluated existing antiviral drugs used for other viral infections, hoping to find immediate options for COVID-19 [1]. Agents such as remdesivir, favipiravir, and hydroxychloroquine were repurposed due to their mechanisms against viral replication. Remdesivir, an antiviral initially developed for Ebola, showed promise due to its ability to inhibit RNA polymerase, which SARS-CoV-2 uses to replicate. Early trials found that remdesivir could reduce recovery times in hospitalized patients, although its effectiveness was later understood to be moderate, especially among patients with severe COVID-19 [2].

Hydroxychloroquine garnered significant attention due to preliminary studies, suggesting it might reduce viral replication. However, larger and more rigorous studies ultimately showed limited efficacy, leading to a decline in its use. Other

early therapeutic avenues included corticosteroids like dexamethasone, which proved to be an essential treatment for severe cases by reducing the inflammatory response associated with severe COVID-19 complications [3 - 5].

### **mRNA Vaccines: A Transformative Approach**

One of the most remarkable advances in SARS-CoV-2 therapeutics was the rapid development of mRNA vaccines. Unlike traditional vaccine platforms, mRNA technology allowed for the swift synthesis of vaccines, which could be adapted quickly to target the virus's specific spike protein, a key component for SARS-CoV-2's entry into human cells. The vaccines by Pfizer-BioNTech (Comirnaty) and Moderna used lipid nanoparticles to deliver mRNA coding for the spike protein into host cells, initiating an immune response without the risk of actual viral infection [6].

mRNA vaccines were transformative due to their speed and efficacy. While traditional vaccine development can take years, mRNA vaccines for COVID-19 were developed, tested, and distributed within a year of the virus's emergence. Clinical trials showed that these vaccines provided high levels of protection against symptomatic COVID-19, significantly reducing the risks of severe disease, hospitalization, and death. Studies indicated efficacy rates above 90% for preventing symptomatic infection during early 2021, leading to widespread adoption [7, 8].

### **Monoclonal Antibody Therapies**

Monoclonal antibodies also emerged as a vital therapeutic tool, especially for patients at risk of severe COVID-19. These laboratory-produced antibodies target specific regions on the spike protein, neutralizing the virus and preventing it from infecting cells. The first monoclonal antibody therapies, like bamlanivimab and the combination therapy of casirivimab and imdevimab, received emergency use authorizations in 2020. These treatments were particularly beneficial for individuals in the early stages of infection and those with risk factors for severe disease [8].

Monoclonal antibodies were a novel approach to treating viral infections on a broad scale. While effective, the emergence of SARS-CoV-2 variants that altered the spike protein challenged the efficacy of these treatments. Researchers quickly adapted, developing new formulations targeting multiple epitopes on the spike protein to counteract escape mutations. This adaptability highlighted the importance of flexible therapeutic designs in combating evolving pathogens like SARS-CoV-2 [8].

## SUBJECT INDEX

### A

- Activated partial thromboplastin time (aPTT) 72, 106
- Acute coronary syndrome (ACS) 39, 44, 74
- Acute myocardial infarction (AMI) 40, 74, 75
- Acute respiratory distress syndrome (ARDS) 4, 39, 60, 63, 88, 89, 92, 108, 109, 193, 201, 203
- Adhesion molecules 64, 91, 199
- Adverse events following immunization (AEFIs) 214, 223
- Angiotensin-converting enzyme II (ACE2) 3, 15, 41, 58, 145
- Antiphospholipid syndrome 47, 80, 91, 92, 146
- Antithrombin III (ATIII) 73, 88
- Arterial thrombosis 37, 38, 45, 46, 48, 49, 50, 59, 60, 61, 97, 129, 130, 144, 203
- Asia-pacific strategy for emerging diseases (APSED) 9

### B

- Bioactive compounds 28
- Biomarkers 20, 45, 46, 48, 51, 81, 129, 202, 206
- Blood coagulation 94, 198
- Blood viscosity 90, 92
- Bronchoalveolar fibrin turnover 108

### C

- Capillary permeability 108
- Cardiovascular disease (CVD) 39, 40, 41, 46, 47, 63, 67, 70, 82, 88, 93, 95, 113
- Case-fatality rate (CFR) 65
- Catheter-directed thrombolysis (CDT) 74
- Cerebral hypoperfusion 97
- Cerebral ischemia 98
- Chronic kidney disease (CKD) 68, 76, 116

- Chronic obstructive pulmonary disease (COPD) 95
- Coagulopathy 40, 109, 112, 121, 123, 148, 149, 198, 199, 201, 202, 204, 205, 206, 207
- Coalition for Epidemic Preparedness Innovations (CEPI) 172, 196
- Complement activation 92, 200, 202
- Computed tomography pulmonary angiography (CTPA) 71, 105, 154
- C-reactive protein (CRP) 47, 49, 51, 66, 129
- Cytokine storm 40, 41, 42, 59, 62, 63, 66, 68, 90, 92, 145, 199, 204, 205, 207

### D

- D-dimer 41, 42, 45, 48, 51, 59, 63, 66, 68, 72, 87, 90, 91, 104, 106, 113, 124, 129, 130, 146, 148, 151, 198, 199, 201, 202, 204, 206
- Damage-associated molecular patterns (DAMPs) 42, 45
- Deep vein thrombosis (DVT) 37, 39, 45, 47, 48, 59, 60, 66, 67, 69, 70, 71, 72, 74, 93, 94, 95, 96, 101, 102, 103, 105, 115, 119, 121, 143, 144, 148, 203
- Dihydroorotate dehydrogenase (DHODH) 20
- Direct oral anticoagulants (DOACs) 50, 51, 75, 81, 83, 101, 110, 111, 112, 114, 120
- Disseminated intravascular coagulation (DIC) 40, 42, 59, 62, 63, 64, 90, 99, 100, 106, 107, 109, 201, 203
- Distal deep vein thrombosis (DDVT) 101

### E

- Electronic health records (EHRs) 162, 164, 212, 214
- Emergency use authorizations (EUs) 172, 175, 176, 194, 212, 215, 217, 218, 220, 223, 225

Endothelial cell dysfunction 43, 58, 59, 63, 64, 66, 67, 68, 89, 90, 91, 92, 145, 146, 199  
Endothelial microparticles 49  
European Medicines Agency (EMA) 79, 152, 171, 174, 212, 214, 220, 223, 225  
Extracranial arterial stenosis (ECAS) 98

## F

Fibrinogen degradation products (FDPs) 201  
Fibrinolysis 64, 71, 90, 91, 108, 146, 186, 201  
Food and Drug Administration (FDA) 26, 171, 174, 176, 212, 220, 223, 225, 226

## G

Genetic predisposition 68, 81, 91, 92  
Geographic information systems (GIS) 164  
Global health security agenda (GHSA) 161  
Global immunization vision and strategy (GIVS) 23  
Global Initiative on Sharing All Influenza Data (GISAID) 21, 82  
Global Outbreak Alert and Response Network (GOARN) 160, 163

## H

Hemostasis 49, 100, 107, 200  
Hereditary thrombophilias 45, 47, 48, 68, 70, 76, 91, 93  
Hormone replacement therapy (HRT) 70, 95  
Hypercoagulability 38, 39, 40, 41, 43, 58, 59, 61, 64, 66, 68, 69, 71, 73, 80, 83, 89, 90, 91, 92, 93, 97, 127, 129, 130, 144, 200, 202, 203  
Hypoxia-inducible factors (HIFs) 92, 98, 201, 204

## I

Immune modulation 207  
Immunogenicity 171  
Infection prevention and control (IPC) 24, 25  
Inflammatory mediators 58, 145, 200  
International Coalition of Medicines Regulatory Authorities (ICMRA) 214  
Ischemic stroke 37, 40, 74, 75, 88, 89, 90, 97, 98, 99, 113, 147, 149, 203

## J

Janus kinase (JAK) 207  
Joint Research Centre (JRC) 19, 20

## L

Low-density lipoprotein (LDL) 97, 98  
Lower- and middle-income countries (LMICs) 196, 197, 210, 211  
Low-molecular-weight heparin (LMWH) 49, 50, 51, 75, 76, 77, 110, 111, 112, 114, 115, 119, 120, 123, 146, 148, 151, 201, 204

## M

Magnetic resonance venography (MRV) 102, 105  
Middle East respiratory syndrome (MERS) 10, 15, 159, 166, 208, 227  
Molecular mimicry 91, 92  
Monoclonal antibodies 120, 126, 192, 194, 195, 216, 217, 220, 223, 224, 226  
Myocardial infarction (MI) 26, 38, 40, 41, 46, 52, 74, 75, 88, 89, 90, 97, 146, 147, 149, 203

## N

Neutrophil extracellular traps (NETs) 41, 45, 49, 51, 62, 92, 109, 145, 146, 200, 206

**P**

Pathogenesis 4, 62, 63, 108, 202  
Pathophysiology 37, 38, 42, 44, 69, 70, 80, 87,  
89, 109, 112, 127, 192, 193, 203, 228  
Post-thrombotic syndrome (PTS) 70, 71, 115  
Prothrombin time (PT) 72, 106, 198, 202  
Proximal deep vein thrombosis (PDVT) 101  
Public health and social measures (PHSM) 23  
Public health emergency of international  
concern (PHEIC) 8, 161, 170  
Pulmonary embolism (PE) 37, 38, 39, 45, 60,  
66, 69, 70, 71, 72, 73, 74, 93, 94, 95, 96,  
101, 102, 103, 104, 105, 113, 119, 144,  
146, 148, 201, 203

**R**

Real-world evidence (RWE) 212, 213, 215,  
217, 220  
Receptor-binding domain (RBD) 41  
Respiratory syncytial virus (RSV) 227

**S**

Severe acute respiratory syndrome (SARS) 2,  
7, 10, 15, 16, 38, 52, 87, 88, 126, 144,  
157, 158, 159, 160, 161, 162, 181, 182,  
183, 185

**T**

Thrombin-antithrombin complex 46, 48, 107  
Thrombocytopenic thrombotic purpura (TTP)  
107  
Thrombosis with thrombocytopenia syndrome  
(TTS) 78, 219  
Thrombotic microangiopathy (TMA) 40, 44,  
107, 109  
Tissue factor pathway inhibitor (TFPI) 42, 46,  
47, 48, 207

**U**

Unfractionated heparin (UFH) 49, 50, 77, 110,  
111, 112, 114, 115, 119, 121, 123  
Universal health coverage (UHC) 184, 185

**V**

Vaccine adverse event reporting system  
(VAERS) 214, 223, 224, 225  
Vaccine-induced immune thrombotic  
thrombocytopenia (VITT) 88, 120, 143,  
144, 151, 152, 225  
Variants of concern (VOCs) 17, 18, 19, 219  
Variants of interest (VOIs) 17, 18  
Venous thromboembolism (VTE) 39, 40, 44,  
60, 61, 65, 68, 69, 93, 103, 104, 110,  
111, 113, 119, 127, 129, 146, 147, 148,  
202, 203

**W**

Willebrand factor (WF) 42, 90, 91, 92, 199  
World Food Programme (WFP) 182  
World Health Organization (WHO) 3, 8, 15,  
17, 18, 30, 31, 32, 82, 125, 157, 158,  
159, 160, 164, 172, 174, 181, 196, 214



## Ravikant Gupta

---

Ravikant Gupta is working as an Associate Professor at the School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Jalandhar, Punjab, India. Dr. Gupta has a decade of pharmaceutical industry experience and has worked in many MNCs such as IPCA, Mylan, and Torrent. Dr. Gupta has more than 12 years of experience in the field of pharmaceuticals. He is a PhD holder in the Pharmaceutics domain and has participated in more than 76 national and international conferences/seminars/webinars/symposia. He has published more than 40 research and review papers in reputed national and international journals and has published 10 books and 25 book chapters. Dr. Gupta is a registered pharmacist and has been awarded the Health Excellence Award, Research Excellence Award, Young Scientist Award, Inspirational Associate Professor Award, and Young Researcher Award.



## Sudha Vengurlekar

---

Sudha Vengurlekar, Professor and Dean, Faculty of Pharmacy, Oriental University, Indore, is an accomplished academican with 21 years of expertise in pharmaceutical education, research, and administration. She has in-depth knowledge of healthcare systems, workflows, and regulatory compliance related to drug design. Her research expertise includes antimicrobial drug design, herbal drug development, and molecular modeling techniques, along with a strong understanding of healthcare technologies and data analysis tools. She has published 70 research articles, 15 book chapters, and 6 books in reputed journals and publications. She has secured grants from AICTE, PCI, and ICMR for conducting various events and has established strong collaborations with industries. Her contributions to scientific committees, editorial boards, and industry collaborations continue to drive advancements in pharmaceutical sciences.



## Sachin Kumar Jain

---

Sachin Kumar Jain is working as Professor and Principal at Oriental College of Pharmacy & Research, Oriental University, Indore, MP (India). Dr. Jain has 18 years of teaching experience. He has received the Best Researcher Award, Best Pharmacy Professional Award, and Young Talent Award at various national and international conferences. Dr. Jain has published more than 12 books with various reputed publishers, including Bentham Science, Taylor and Francis, Springer Nature, Cambridge Scholar Library, Iterative International Publishers, and many more. Dr. Jain is an active peer reviewer for various national and international journals with high impact factors and reputed publishers. Dr. Jain has published more than 105 research and review articles in national and international journals with good indexing. Dr. Jain has also published more than 18 book chapters with international publishers (Bentham Science, Springer Nature, Taylor and Francis, Cambridge Scholar Library, Iterative International Publishers).